Correlation Between Serum Cardiac Markers and Myocardial Infarct Size Quantified by Myocardial Perfusion Imaging in Patients With Hypertrophic Cardiomyopathy After Alcohol Septal Ablation




Myocardial infarct (MI) size is a well-established prognostic marker but the association of serum markers with MI size, as measured by myocardial perfusion imaging (MPI), has not been well studied in patients with hypertrophic cardiomyopathy (HC) after alcohol septal ablation (ASA). Creatine kinase (CK), CK-MB, troponin I, and brain natriuretic peptide were measured before and at multiple points after ASA in patients with HC and were correlated with MI size measured by MPI. MPI at rest was performed in 54 patients with HC at a median of 2 days after ASA. CK, CK-MB, and troponin I increased after ASA to peak levels at 12 hours and their cumulative levels (area under the curve) showed significant correlation with size of MI by MPI (r = 0.544, 0.408, and 0.477, p <0.001, 0.003, and 0.001, respectively). The best marker was level of CK at 12 hours (r = 0.609, p <0.0001) after ASA. Brain natriuretic peptide level did not change significantly after ASA (p = 1.0) and only weakly correlated with MI size by MPI (r = 0.130, p = 0.007). In conclusion, CK, CK-MB, and troponin I measured at 12 hours, at peak, and as the area under the curve correlated well with infarct size, but CK level at 12 hours was the best marker. CK continues to be a useful marker of MI size despite the introduction of newer, more specific markers, especially when infarct onset is known with certainty as in patients with HC undergoing ASA.


The aim of this study was to compare various cardiac biomarkers in estimating myocardial infarct (MI) size, using myocardial perfusion imaging (MPI) as the reference standard, in patients with hypertrophic cardiomyopathy (HC) after alcohol septal ablation (ASA), because in such patients the onset of MI is known with certainty.


Methods


Patients with HC who underwent ASA at the hospital of the University of Alabama at Birmingham from September 2003 to April 2008 were included in the study. ASA is performed at our institution for patients with HC and severe symptoms that are unresponsive to maximally tolerated medical therapy and a left ventricular outflow gradient ≥30 mm Hg at rest or ≥50 mm Hg with provocation.


MPI was performed at a median of 2 days after ASA (interquartile range 1 to 2) using gated single-photon emission computed tomography 60 minutes after intravenous injection of technetium-99m sestamibi 20 to 40 mCi at rest. Images were acquired with a dual-head detector (Phillips, Miltipas, California) with and without attenuation correction using emission line source. Images were obtained in 32 projections (30 seconds/projection) using 180° anterior elliptical arc with 20% energy window centered on 140 keV. The RR cycle was divided into 8 to 16 frames and gating was done with a ±50% window. Rotating images were reviewed for motion and reconstructed with filtered backprojection using Butterworth filter and realigned to the long axis of the heart. The present results are without attenuation correction. Images were interpreted quantitatively using an automated operator-independent method based on polar maps and a customized database of patients with HC as previously described. It is important to note that using proprietary software will lead to errors because this population is known to have asymmetric septal hypertrophy. Images were interpreted blindly without knowledge of serum markers and vice versa.


ASA was performed as previously described. Briefly, a Sprinter 1.5- to 3.0- × 6-mm balloon (Medtronic, Minneapolis, Minnesota) was inflated in the septal artery and a small amount of absolute alcohol was injected with the balloon in the inflated position to prevent leakage into the main artery. The balloon was deflated 5 minutes after infusion of alcohol. All procedures were guided by contrast echocardiography.


Serum levels of creatine kinase (CK), CK-MB, cardiac troponin I, and brain natriuretic peptide were routinely checked before ASA and then at 6, 12, 18, 24, 30, 36, and 42 hours afterward. All serum markers were analyzed in the local institutional laboratory.


All patients gave informed consent for their procedure after understanding the available alternatives. This study was a retrospective review of their medical records and the laboratory and imaging results. Chart review was approved by the local institution review board.


All statistical analyses are carried out using SPSS 11.5 for Windows (SPSS, Inc., Chicago, Illinois). Continuous variables are presented as mean ± SD and discrete variables as frequencies and percentages. Chi-square test was used for categorical variables when appropriate. Linear regression analysis was used to determine the relation between serial markers and defect size as determined by MPI. Serial changes in serum markers were analyzed using analysis of variance for repeated measures. All tests were 2-tailed, and a p value ≤0.05 was considered statistically significant.




Results


During the specified period 66 patients with HC underwent ASA at our institution. MPI studies were available for assessment of infarct size in 54 patients (82%). Serum markers were available for all patients at some of the specified time points. Baseline characteristics of patients are listed in Table 1 and medications at the time of their ASA are listed in Table 2 . These characteristics were similar between the 2 populations.



Table 1

Baseline characteristics of study cohort



































































































Characteristic Entire Cohort Patients With MPI p Value
(n = 66) (n = 54)
Age (years) 52.0 ± 15.3 52.1 ± 14.4 1.0
Female gender 36 (55%) 30 (56%) 1.0
Caucasian 56 (85%) 46 (85%) 1.0
Diabetes mellitus 14 (21%) 13 (24%) 0.8
Hypertension 35 (53%) 30 (56%) 0.9
Hyperlipidemia 27 (41%) 24 (44%) 0.7
Coronary artery disease 13 (20%) 10 (19%) 1.0
Atrial fibrillation 12 (18%) 8 (15%) 0.7
Ventricular tachycardia 4 (6%) 3 (6%) 1.0
Creatinine (mg/dl) 1.04 ± 0.3 1.03 ± 0.3 0.8
Tobacco use
Ever use 52 (79%) 44 (81%) 0.9
Current use 16 (24%) 11 (20%) 0.7
Chronic obstructive pulmonary disease 9 (14%) 7 (13%) 1.0
Family history
Suggestive of hypertrophic cardiomyopathy 12 (18%) 11 (20%) 0.8
Sudden death 11 (17%) 11 (20%) 0.6

Values are means ± SDs or numbers of subjects (percentages).

Patient is considered to have hyperlipidemia if prescribed medications to control cholesterol and/or triglyceride levels.


Patient is considered to have coronary artery disease if area stenosis in any coronary artery or its major branches is >50%.



Table 2

Medication received by patients at time of alcohol septal ablation






















































Medication Entire Cohort Patients With MPI p Value
(n = 66) (n = 54)
Aspirin 34 (52%) 29 (54%) 0.9
Clopidogrel 6 (11%) 4 (7%) 1.0
β blocker 56 (85%) 46 (85%) 1.0
Calcium channel blocker 24 (36%) 18 (33%) 0.8
Statin 25 (38%) 22 (41%) 0.9
Diuretic 29 (44%) 24 (44%) 1.0
Warfarin 10 (15%) 7 (13%) 0.9
Amiodarone 7 (11%) 5 (9%) 1.0


The ASA procedure was technically successful in all patients. The amount of absolute alcohol injected per patient was 2.21 ± 1.15 ml and the mean diameter of the balloons inflated in the coronary arteries was 2.17 ± 0.33 mm (range 1.3 to 3.0). On average, patients stayed in the hospital 4.3 ± 2.6 days (range 2 to 14).


All 3 serum markers of myocardial necrosis (CK, CK-MB, and troponin I) showed a pattern of increase after alcohol infusion to peak levels at 12 hours and then a trend down toward baseline (p <0.0001; Figure 1 , Table 3 ). Brain natriuretic peptide was increased at baseline but did not show any appreciable change after ASA (p = 1.0). Alcohol infusion produced, in general, small infarcts at the base of the left ventricular septum. The infarct size was quantified as described in the Methods section ( Table 4 ).




Figure 1


Change of serum markers after MI. Concentrations of CK (A) , CK-MB (B) , troponin I (C) , and brain naturetic peptide (BNP) (D) are shown at different time points after infusion of alcohol in a septal coronary artery of patients with HC. Time points are listed as median and interquartile range with the 95th percentile confidence interval. The number of patients with available data at each time point is listed below the graph. A clear peak at 12 hours is seen for CK, CK-MB, and troponin I, after which the concentrations trend back toward baseline. There is no clear change in BNP after MI when followed serially for 42 hours. It is noted that BNP is significantly increased at baseline in these symptomatic patients with HC.


Table 3

Serial serum cardiac markers in hypertrophic cardiomyopathy patients after alcohol septal ablation






















































Baseline 6 Hours 12 Hours 18 Hours 24 Hours 30 Hours 36 Hours 42 Hours
Creatine kinase (U/L) 130 ± 79 (n = 46) 1,310 ± 634 (n = 63) 1,474 ± 758 (n = 60) 1,288 ± 741 (n = 61) 992 ± 589 (n = 51) 761 ± 476 (n = 45) 633 ± 449 (n = 39) 499 ± 319 (n = 34)
Creatine kinase-MB (U/L) 6 ± 18 (n = 37) 150 ± 83 (n = 61) 163 ± 87 (n = 57) 127 ± 81 (n = 59) 81 ± 60 (n = 50) 49 ± 44 (n = 44) 35 ± 37 (n = 39) 19 ± 20 (n = 35)
Troponin I (ng/ml) 0.5 ± 1.6 (n = 33) 44 ± 35 (n = 49) 75 ± 40 (n = 51) 72 ± 38 (n = 47) 61.0 ± 33 (n = 48) 53 ± 27 (n = 40) 45 ± 23 (n = 30) 36 ± 15 (n = 32)
Brain natruretic peptide (pg/ml) 307 ± 382 (n = 54) 362 ± 691 (n = 45) 375 ± 601 (n = 44) 396 ± 571 (n = 39) 386 ± 586 (n = 32) 477 ± 600 (n = 33) 387 ± 540 (n = 28) 436 ± 496 (n = 24)


Table 4

Infarct size by myocardial perfusion imaging in patients with hypertrophic cardiomyopathy after alcohol septal ablation (n = 54)



















Variable Mean ± SD
Left ventricular volume (ml) 176 ± 40
Left ventricular mass (g) 185 ± 42
MI size (percent left ventricle) 10.5 ± 10.6
MI mass (g) 19.1 ± 18.6


Serum markers of myocardial necrosis after ASA showed significant correlations with the size of the infarct as assessed by MPI ( Figure 2 ); the highest correlation was with CK at 12 hours, which was even better than the total amount released as measured by the area under the curve for each patient. Brain natriuretic peptide at baseline was only weakly correlated with infarct size ( Table 5 ). Multivariate models using linear regression were then constructed for the prediction of the size of the infarct as assessed by MPI using the 3 serum markers (CK, CK-MB, and troponin I) measured at 12 hours, at peak level for each patient, or as the total amount released. In each instance the model showed statistical significance in the prediction of the infarct size, with the highest contribution coming from CK. At 12 hours, CK was the only variable that showed statistical significance in the multivariate model with a slope of 0.729 ( Table 6 ).




Figure 2


Correlation between serum markers and infarct mass measured with MPI. There is a linear correlation between CK (A) and troponin I (B) measured at 12 hours after inducing MI by the infusion of alcohol in a septal coronary artery of patients with HC. The correlation coefficient (r) is shown at the top of the graph with the corresponding p value. The regression line (straight line) is bounded by the 95th percentile confidence interval.


Table 5

Factors correlated with size of infarct as assessed by myocardial perfusion imaging




























































r p Value
Creatine kinase
At 12 hours 0.609 <0.0001
Peak 0.581 <0.0001
Cumulative 0.544 <0.0001
Creatine kinase-MB
At 12 hours 0.446 0.002
Peak 0.454 0.001
Cumulative 0.408 0.003
Troponin I
At 12 hours 0.480 0.002
Peak 0.445 0.001
Cumulative 0.477 0.001
Brain natruretic peptide at baseline 0.130 0.007

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Dec 23, 2016 | Posted by in CARDIOLOGY | Comments Off on Correlation Between Serum Cardiac Markers and Myocardial Infarct Size Quantified by Myocardial Perfusion Imaging in Patients With Hypertrophic Cardiomyopathy After Alcohol Septal Ablation

Full access? Get Clinical Tree

Get Clinical Tree app for offline access